Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.

The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.

A back-loaded deal with CureVac moves Lilly into an emerging field that seeks to use mRNA to guide immune attacks on tumors.

Big Pharma-backed antifibrotic startup Blade has triggered the remaining tranche of last summer’s $45 million series B after placing its bets on a leading…

Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.

Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.

Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.

Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon.

The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.

AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.